Medicamen Organics SME IPO Details, Financials, Valuation & Peers
Get everything you need to know about the Medicamen Organics IPO. Explore Medicamen Organics IPO details, including IPO dates, financial statements, valuation, peer comparison, and more.
Overview
Medicamen Organics Limited is a pharmaceutical company specializing in the development, manufacturing, and distribution of a broad range of pharmaceutical dosage forms. These include generic tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders. Operating primarily as a contract and third-party manufacturer, the company serves both government and private institutions. Medicamen Organics markets its products domestically and internationally through third-party distributors and has begun establishing a direct presence in international markets.
Key Points:
- Products and Services:
- Offers a wide range of pharmaceutical products, including anti-bacterial, anti-diarrheal, anti-fungal, anti-malarial, anti-diabetic, proton pump inhibitors, anti-histamines, anti-hypertensives, anti-lipidemic drugs, anti-parasitics, multivitamins, multiminerals, and NSAIDs.
- Product forms include tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders.
- Manufacturing Facilities:
- Two WHO GMP approved facilities located in Haridwar, Uttarakhand, covering 21,536 sq. ft.
- Facilities equipped with a quality control department and in-house testing laboratory.
- Market Reach and Expansion:
- Products marketed across India and internationally in African, CIS, and Southeast Asian countries, including Congo, Benin, Togo, Senegal, Philippines, Myanmar, Mozambique, Kyrgyzstan, and Kenya.
- Direct export operations initiated in Burundi during fiscal 2023 and 2024.
- Focus on expanding international presence and maintaining a robust domestic market.
- Business Models:
- Contract Manufacturing: Operates a B2B model partnering with pharmaceutical companies to manufacture products marketed by third parties. Holds product development rights, while partners own marketing rights.
- Government Contracts: Supplies products through government tenders to hospitals, departments, PSUs, and armed forces, benefiting from bulk quantities and committed volumes.
- Product Categories:
- Capsules: Includes formulations for hyperacidity, immunosuppression, and antiviral treatment.
- Ointments/External Preparations: Produces antifungal, anti-bacterial, and anti-inflammatory creams and gels.
- Suspensions: Offers cough syrups, multivitamin/mineral supplements, antacids, iron supplements, and more.
- Dry Powder Sachets: Manufactures pre and probiotics, diclofenac granules, etc.
- Tablets: Produces ferrous and folic acid tablets, among others, to treat iron deficiencies and other conditions.
Objects of the Issue
- Product registration in the international markets
- Plant updation and increase in production capacity
- To meet Working Capital requirements
- General corporate purposes
IPO Details
Discover essential information crucial for understanding an IPO, including the Price Band, Fresh Issue, Offer For Sale, Total IPO Size and more. Explore these key details to gain insight into the company's public offering.
| Fields | Details |
|---|---|
| IPO Dates | 21 Jun - 25 Jun 2024 |
| IPO Price Band | ₹ 32 - 34 per share |
| Fresh Issue | Upto 31,00,000 Shares |
| Offer For Sale | NIL |
| Total IPO Size | Approx ₹ 10.54 crore |
| Face Value | ₹ 10 |
| Listing On | NSE |
IPO Timeline
Explore important dates like IPO opening, closing, listing and others, outlining the journey of the Public Offering. This will help you grasp the entire IPO journey effortlessly.
| Event | Date |
|---|---|
| IPO Opening Date | 21 Jun 2024 |
| IPO Closing Date | 25 Jun 2024 |
| Basis Of Allotment | 26 Jun 2024 |
| Refunds | 26 Jun 2024 |
| Demat Transfer | 27 Jun 2024 |
| IPO Listing Date | 28 Jun 2024 |
Financial Statements
Explore a comprehensive financial data table showcasing key metrics including revenue, expenses, net income, and others. Gain valuable insights about the company's financial performance at a glance, facilitating informed decision-making and strategic planning for subscribing to the IPO.
| Period Ended | 31st March 2021 | 31st March 2022 | 31st March 2023 | 31st March 2024 |
|---|---|---|---|---|
| Total Income | 25.06 | 21.19 | 22.96 | 25.29 |
| Total Expenses | 24.57 | 20.93 | 21.60 | 21.90 |
| Net Profit/Loss | 0.30 | 0.10 | 0.97 | 2.40 |
| NPM (*) | 1.19 | 0.44 | 4.38 | 9.51 |
| Total Assets | 26.34 | 27.54 | 32.59 | 38.58 |
| Total Liabilities | 18.88 | 19.53 | 23.61 | 23.40 |
* NPM represents the net profit margin, calculated as a percentage. All other figures are presented in crore (₹cr)
Valuation
Uncover significant valuation metrics such as EPS (Earnings Per Share), ROE (Return on Equity), ROCE (Return on Capital Employed), D/E Ratio (Debt-to-Equity Ratio), Current Ratio, and EBITDA Margin. These key indicators offer insights into the company's financial standing and performance, aiding in informed investment decisions.
| Period Ended | 31st March 2021 | 31st March 2022 | 31st March 2023 | 31st March 2024 |
|---|---|---|---|---|
| EPS | 0.50 | 0.17 | 1.62 | 3.18 |
| ROE (%) | 0.04 | 0.01 | 0.12 | 14.50 |
| ROCE (%) | 5.68 | 4.09 | 9.71 | 19.90 |
| D/E Ratio | 1.28 | 1.36 | 1.38 | 1.28 |
| Current Ratio | 0.86 | 0.88 | 0.95 | 1.25 |
| EBITDA MARGIN (%) | 6.57 | 6.71 | 12.12 | 18.80 |
* Compiled from DRHP/RHP for valuation purposes.
Peer Comparison
Compare key financial metrics with industry peers to gain valuable insights into the company's performance compared to its competitors.
| Name | Total Income | P/E | EPS | RoNW | NAV |
|---|---|---|---|---|---|
| Medicamen Organics Limited | 25.29 | 10.69 | 3.18 | 15.83 | 17.66 |
| Brooks Laboratories Ltd | 63.41 | 10.60 | -12.57 | -28.26 | 30.10 |
| Cian Healthcare Ltd | 68.10 | 53.84 | 0.43 | 1.75 | 22.40 |
| Zenotech Laboratories Ltd | 43.51 | 38.76 | 1.90 | 14.08 | 14.20 |
* Revenue in (₹cr), RoNW in (%), EPS, NAV in (₹). P/E ratio is based on the highest price from the IPO price band.
Subscription Data from NSE and BSE
| Investor Type | Subscribed |
|---|---|
| Qualified Institutional Buyer (QIB) | 173.03 |
| Non-Institutional Investor (NII/HNI) | 1343.83 |
| Retail Individual Investor (RII) | 1309.77 |
| Total | 993.56 |
* All figures represent multiples of the subscription. Check subscriptions for other ongoing issues here.
IPO Registrar
KFin Technologies Limited
Phone: +91 40 6716 2222/ 18003094001
Email: einward.ris@kfintech.com
Website: www.kfintech.com
Company Promoters
- MR. BAL KISHAN GUPTA
- MR. ASHUTOSH GUPTA
Lead Managers
- GYR CAPITAL ADVISORS PRIVATE LIMITED
Company Address
Medicamen Organics Limited
10 Community Centre No 2 Ashok Vihar Phase II, New Delhi, Delhi, 110052, India.
Phone: +91-9818222845
Email: cs@mediorganics.in
Website: www.medicamenorganics.com
FAQs
- What is the issue size of the Medicamen Organics SME IPO?The Medicamen Organics SME IPO has an issue size of Approx ₹ 10.54 crore. This includes a fresh issue of Upto 31,00,000 Shares and an offer for sale (OFS) of NIL.
- What is the price band of the Medicamen Organics IPO?The price band for the Medicamen Organics IPO is ₹ 32 - 34 per share.
- What are the bidding dates for the Medicamen Organics IPO?The Medicamen Organics IPO will open for bidding on 21 Jun 2024 and close on 25 Jun 2024.
- What is the allotment date for the Medicamen Organics IPO?The allotment date for the Medicamen Organics IPO is 26 Jun 2024.
- What is the listing date for the Medicamen Organics IPO?The listing date for the Medicamen Organics IPO is 28 Jun 2024.
- What is the Medicamen Organics IPO grey market premium?The grey market premium (GMP) for the Medicamen Organics IPO is currently at ₹70, with an expected listing gain of approximately 205.88%. Remember, the grey market premium is not an official indicator, but it reflects market perception and demand for the IPO shares.